Published on 22 Nov 2021 on Zacks via Yahoo Finance
Moderna ETFs to Rally on Positive COVID-19 Booster Shot News
Investors can cheer another encouraging development related to the COVID-19 vaccines. The FDA has broadened the emergency use authorization (EUA) approval of Moderna’s MRNA COVID-19 vaccine booster shot at the 50 µg dose level to all adults aged 18 and above. The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (“ACIP”) has also issued a recommendation suggesting a booster dose. In fact, all the 11 ACIP members unanimously recommended the booster dose.
The authorization has come at a time when travel restrictions are easing and the outbreak is spreading alarmingly in Europe. Thus, the approval can be further helpful in containing the coronavirus outbreak in the United States. Moderna’s sales figures are also expected to get the boost with the latest approval.
Investors willing to ride Moderna’s gains from the latest nod on the booster shots can consider ETFs like ETFMG Treatments Testing and Advancements ETF GERM, VanEck Biotech ETF BBH, iShares Biotechnology ETF IBB and iShares Genomics Immunology and Healthcare ETF IDNA.